Format

Send to

Choose Destination
Oncotarget. 2016 Jul 19;7(29):44876-44878. doi: 10.18632/oncotarget.10381.

Rapamycin in aging and disease: maximizing efficacy while minimizing side effects.

Author information

1
Department of Genetics, Albert Einstein Medical College, New York, NY, USA.
2
Department of Pathology, University of Washington, Seattle, WA, USA.

Abstract

Experimental geroscience has identified rapamycin as a top candidate for promoting healthy aging and longevity in mammals. As multiple independent studies have successfully reproduced the lifespan and healthspan promoting effects of rapamycin, the focus has shifted to possible translational use. While a promising compound, clinical use of rapamycin is limited by concerns of side effects associated with the drug. Studies aimed at defining optimal dosage regimen, delivery route, and formulation will allow for benefits to be maximized while reducing side effects.

KEYWORDS:

healthspan; mTOR; mitochondria; mitochondria disease; target of rapamycin

PMID:
27384492
PMCID:
PMC5216691
DOI:
10.18632/oncotarget.10381
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center